Ireland - Re-Imbursed Pharmaceutical Market
Since 2014, Ireland Re-Imbursed Pharmaceutical Market was down by 1.1points year on year. At 15.5 Percent of Generics in Value in 2019, the country was number 14 among other countries in Re-Imbursed Pharmaceutical Market. Ireland is overtaken by Netherlands, which was ranked number 13 at 19.7 Percent of Generics in Value and is followed by Belgium with 13.9 Percent of Generics in Value. Austria topped the ranking with 52.2 Percent of Generics in Value in 2019, that is an increase of 2.8points compared to 2018. United Kingdom, Turkey and New Zealand respectively ranked number 2, 3 and 4 in this ranking. Denmark recorded the best 5 years average growth at +6.9points per year, while Slovakia witnessed the worst performance at -7.8points per year.
Loading...
| Date | Percent of Generics in Value |
|---|---|
| 2019 | 15.50 |
| 2018 | 14.90 |
| 2017 | 14.60 |
| 2016 | 15.60 |
| 2015 | 16.20 |
How does Ireland rank in Re-Imbursed Pharmaceutical Market?
| # | 17 Countries | Percent of Generics in Value | Last | YoY | 5‑years CAGR | ||
|---|---|---|---|---|---|---|---|
| 1 |
#1
Austria
|
52.20 % | 2019 | +2.8 % | +2.2 % | View data | |
| 2 |
#2
United Kingdom
|
38.50 % | 2019 | +2.1 % | +2.6 % | View data | |
| 13 |
#13
Netherlands
|
19.70 % | 2019 | -1.5 % | +3.6 % | View data | |
| 14 |
#14
Ireland
|
15.50 % | 2019 | +4.0 % | -1.1 % | View data | |
| 15 |
#15
Belgium
|
13.90 % | 2019 | +4.5 % | +0.9 % | View data | |